摘要:目的: 通過分析健康體檢者心電圖異常的發生率及類型,為當地人群心血管疾病的早期診斷、早期治療提供依據。 方法 : 采用光電三道心電圖機在體檢者安靜休息狀態下以常規12道描記,時間在15秒左右。按3個年齡段對健康體檢患者心電圖進行分組分析,同時對心電圖異常者做病因診斷。 結果 : 1356例完成十二導聯心電圖監測,異常心電圖占2257%,其中STT異常占首位1123%。41～60歲人群心電圖異常的檢出率男性較高,且多伴高血壓、血糖異常、血脂異常等; 61～81 歲組人群心電圖異常的檢出率最高,且多已存在糖尿病、高血壓和冠狀動脈供血不足等疾病。 結論 :定期進行心電圖檢查,對早期發現、預防、診斷心血管疾病有重要意義。Abstract: Objective: To provide evidences for the early diagnosis and treatment of cardiovascular diseases through the analysis of the electrocardiographic abnormality and category. Methods : Analyzing the health examination electrocardiogram according to age and etiological diagnosis were committing to cases with electrocardiographic abnormality. Results : 1356 cases finished the electrocardiography. The rate of electrocardiographic abnormality was 2257%, and the STT abnormality hold the first place (1123%). The rate of electrocardiographic abnormality increased with the increasing age and it is highest in the 61~81 ages. Conclusion : Regular health examination by electrocardiography is important for early diagnosis, prevention and treatment of potential cardiovascular disease.
Objective T o observe the efficacy and safety of intravitreal injection of ranibizumab (Lucentis) for 12 consecutive months treating exudative age-related macular degeneration (EAMD). Methods This is an open and prospective study without control trial. Twenty-two eyes from 22 patients (18 males and 4 females) with EAMD diagnosed by fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were enrolled in this study. The patients aged from 46 to 79 years with the mean of 68.2plusmn;9.3 years. All of the patients received intravitreal injection of ranibizumab (0.5 mg, 0.05 ml) once a month for 12 consecutive months. The best-corrected visual acuity (BCVA) was obtained using the international standard visual acuity chart (converted into logMAR for statistical analysis). Central retinal thickness (CRT) was measured by optical coherence tomography (OCT) before and after each monthly treatment. Intraocular pressure (IOP) was measured using non-contact tonometry before treatment and 1 hour and 1 day after treatment. FFA and ICGA were performed every 3 months. The BCVA was 0.01 -0.9 with the average of 0.26plusmn;0.22. The average logMAR BCVA was 0.76plusmn;0.44, the CRT was 182-559 mu;m with the mean of (302.62plusmn;90.18) mu;m, and the IOP was normal before treatment. Only 13 of 22 patients completed 12 months of follow-up. The BCVA, CRT and IOP after treatment were compared with baseline using paired t test. Results Of all the 22 patients, the mean logMAR BCVA at 1 and 3 months after treatment were 0.52plusmn;0.32 and 0.37plusmn;0.27 respectively, both of which were significantly different compared with before treatment (t=4.518, 6.237;P＜0.05). Of the 13 patients, the mean logMAR BCVA at 1, 3 and 12 months after treatment was 0.51plusmn;0.34, 0.35plusmn;0.26, 0.34plusmn;0.30 respectively. All of these measures were significantly different compared with 0.74plusmn;0.37 before treatment (t=3.443, 5.438, 4.756;P＜0.05) . The mean CRT at 1, 3 and 12 months after treatment were (228.85plusmn;54.93), (231.00plusmn;38.94) and (262.92plusmn;70.48) mu;m. There were significant differences among before and 1, 3 months after treatment (t=2.914, 3.199;P＜0.05), but not between before and 12 months after treatment (t=1.408, P＞0.05). The first 3 injections contributed to the most BCVA gain with 6 patientsprime; BCVA increasing from 0.1- 0.5 to 0.5 or above. The greatest CRT reduction was obtained at 1 month after the first injection. IOP increased 1 hour after treatment and recovered within 1 day. No intravitreal injection-related side effects such as endophthalmitis were observed during the follow-up period. Conclusions Monthly intravitreal injections of ranibizumab may improve BCVA and macular edema. There was no adverse event during the follow-up duration.
